The Phaserl


Trump’s Pick for FDA Chief Has Drug and Biotech Industry Ties

by Julie Fidler, Natural Society:

President Trump’s pick for head of the FDA, Dr. Scott Gottlieb, has taken more than $400,000 from drug makers in the last few years alone, and Gottlieb has deep ties to the pharmaceutical industry. [1]

Gottlieb has testified multiple times on Capitol Hill concerning complex drug pricing issues, and is largely approved of by drug companies and pharmaceutical investors for FDA head. He’s on the boards of directors of several small drug and biotech companies, while also serving as an adviser to GlaxoSmithKline PLC. [2]

Brian Skorney, an investment analyst at Robert W. Baird, wrote in a research note:

“Thank God it’s Gottlieb. We view this as a favorable development for the sector.” [2]

Gottlieb is a former FDA deputy commissioner who has advocated further expediting the approval process for new medical products. He has spent the last decade as a partner at New Enterprise Associates, a large venture fund with investments in the life sciences, medical technology, and healthcare services.

These are just some of his links to the pharmaceutical industry.

Mizuho Securities USA Inc. conducted a survey of 53 pharmaceutical executives and found that 72% favored Gottlieb over other potential candidates.

Michael Carome, director of Public Citizen’s health research group and a physician, said in a statement:

“Gottlieb is entangled in an unprecedented web of Big Pharma ties. He has spent most of his career dedicated to promoting the financial interests of the pharmaceutical industry, and the U.S. Senate must reject him.” [3]

Read More @

Help us spread the ANTIDOTE to corporate propaganda.

Please follow SGT Report on Twitter & help share the message.

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>